Trial Profile
A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second Line Cervical Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Nov 2022
Price :
$35
*
At a glance
- Drugs Balstilimab (Primary)
- Indications Adenocarcinoma; Carcinoma; Cervical cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Registrational; Therapeutic Use
- Sponsors Agenus
- 02 Nov 2022 Status changed from active, no longer recruiting to completed.
- 20 Oct 2022 This trial has been Discontinued in Poland, according to European Clinical Trials Database record.
- 13 Aug 2022 This trial has been Discontinued in Spain, according to European Clinical Trials Database record.